You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Test volumes, revenues per test and costs per test improved during the quarter, the company said.
Adaptive said that Q4 clinical testing volume for its ClonoSeq sequencing assay for minimal residual disease increased 66 percent to 3,218 tests.
Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.
Palmetto has expanded coverage of the ClonoSeq assay to include monitoring MRD testing for patients with chronic lymphocytic leukemia (CLL.)
The company has multiple companion diagnostics partnerships in the works, with new tests on the way in 2020, and new plans for next-generation sequencing.
In a proof-of-principle study, Ohio State University researchers compared the nanopore sequencing assay to short-read sequencing and capillary electrophoresis.
The team will present the results to the US Food and Drug Administration as part of a 510(k) application in order to commercialize the technology with Biofluidica.
In the long term, the company is developing a plan to create more tests based on its technology, which digitizes blood samples and turns them into images.
The single-cell genomics firm will collaborate with Fred Hutchinson Cancer Research Center on a targeted sequencing panel for MRD monitoring in AML.
The in vitro diagnostic test can deliver molecular results from whole blood samples in less than three hours, the company said.